According to a recent press release, the telemedicine service provider t+ Medicla has linked up with diabetes company Lifescan, one arm of pharmaceutical giant Johnson and Johnson .
Lifescan manufacture and sell blood glucose monitors and test strips for diabetic use. T+ Medical will now be able to use the One Touch Ultra system technology in order to collect blood glucose readings.
T+diabetes, the diabetes-related software created by T+ gathers the data and sends it to a central database. This information is then analysed, and translated for the use of patients. Patients can then view these graphs over either mobile phones or the internet .
The CEO of T+ Medical, Tim Clover, reportedly commented: “This agreement brings together two complementary technologies and offers improved clinical outcomes and services to patients while creating the opportunities for substantial savings for healthcare providers. Lifescan will be able to expand our commercial efforts while still collaborating on developing the product further and investing in clinical trials to quantify the cost and clinical outcomes.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…